Syphilis Testing Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The syphilis testing market comprises a range of diagnostic tools used to identify syphilis infections, including laboratory-based immunoassays, rapid point-of-care tests, and traditional screening methods such as the Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) tests. Growing alongside broader trends in infectious disease diagnostics, the market addresses a persistent global health concern with significant regional variation in disease burden and testing infrastructure.

• •Detects Treponema pallidum infection through laboratory and rapid diagnostic tests
• •Market valued at approximately $1.61 billion in 2025 with projected 4.5% annual growth
• •Historical growth from $1.1 billion in 2020 reflects rising screening demand globally

Rising global incidence of sexually transmitted infections, including significant resurgences in syphilis across multiple regions, is a primary catalyst for market expansion. Government-backed prenatal screening mandates and routine sexually transmitted infection testing programs in both developed and developing nations are substantially increasing test volumes. Additionally, the introduction of advanced immunoassay technologies offering higher sensitivity and specificity is encouraging laboratories and clinics to adopt modern testing platforms.

• •Increasing STI prevalence and government-mandated prenatal and routine screening programs
• •FDA approvals of next-generation syphilis immunoassays expanding product availability
• •Growing adoption of automated laboratory systems and point-of-care testing in clinical settings

The market is typically segmented by test type, including laboratory-based immunoassays, rapid tests, and other screening methodologies, as well as by end-user such as hospitals, diagnostic laboratories, and public health facilities. Geographically, North America and Europe hold substantial market shares due to well-established healthcare infrastructure and high testing penetration, while Asia-Pacific and Latin America are emerging as high-growth regions driven by expanding healthcare access and rising disease awareness.

• •North America leads the market, supported by advanced healthcare infrastructure and strong regulatory frameworks
• •Asia-Pacific and Latin America show accelerating growth due to improved diagnostic access and rising STI rates
• •Laboratory immunoassays remain the dominant test category, with rapid diagnostic tests gaining share

What are the recent trends and outlook?

The market is trending toward decentralized testing, with point-of-care syphilis diagnostics gaining traction due to their ability to deliver rapid results in community and resource-limited settings. Integration of syphilis testing with broader sexually transmitted infection panel testing and adoption of digital laboratory platforms are reshaping diagnostic workflows. Projections indicate continued steady growth through 2035, supported by sustained public health investment, ongoing product innovation, and expanding screening coverage in underserved populations.

• •Point-of-care and home-based testing options are expanding access in underserved and rural populations
• •Multiplex panels combining syphilis with other STI tests are becoming standard in clinical laboratories
• •Market projected to reach approximately $2.3 billion by 2034, reflecting sustained 4.5% CAGR trajectory